AR005945A1 - Composicion farmaceutica para la modulacion inmunitaria - Google Patents
Composicion farmaceutica para la modulacion inmunitariaInfo
- Publication number
- AR005945A1 AR005945A1 ARP970100701A ARP970100701A AR005945A1 AR 005945 A1 AR005945 A1 AR 005945A1 AR P970100701 A ARP970100701 A AR P970100701A AR P970100701 A ARP970100701 A AR P970100701A AR 005945 A1 AR005945 A1 AR 005945A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- pharmaceutical composition
- adjuvant
- cells
- vaccine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000036039 immunity Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000002671 adjuvant Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010039918 Polylysine Proteins 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 abstract 1
- 229920001308 poly(aminoacid) Polymers 0.000 abstract 1
- 108010011110 polyarginine Proteins 0.000 abstract 1
- 229920000656 polylysine Polymers 0.000 abstract 1
- 230000002787 reinforcement Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica que contiene al menos un péptido de acción inmunomoduladora junto con un adyuvante. El péptido se deriva de un agentepatógeno o de un antígeno de tumores. El adyuvante tiene la capacidad de aumentar lafijación del péptido a las células del individuo a tratar o lapenetración del péptido en las células y de determinar un refuerzo de la acción inmunomoduladora del péptido. Adyuvantes preferidos son poliaminoácidosde carácter básico, talescomo poliarg inina o polilisina que eventualmente están conjugados con un ligando celular, por ejemplo un resto de hidrato decarbono o transferrina. La composición sirve sobre todo para la aplicación como vacuna, por ejemplo como vacunacontra tumores.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19607044A DE19607044A1 (de) | 1996-02-24 | 1996-02-24 | Tumorvakzine und Verfahren zu ihrer Herstellung |
DE19638313A DE19638313C2 (de) | 1996-09-19 | 1996-09-19 | Pharmazeutische Zusammensetzung für die Immunmodulation |
DE19648687A DE19648687A1 (de) | 1996-11-25 | 1996-11-25 | Pharmazeutische Zusammensetzung für die Immunmodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
AR005945A1 true AR005945A1 (es) | 1999-07-21 |
Family
ID=27215945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100701A AR005945A1 (es) | 1996-02-24 | 1997-02-21 | Composicion farmaceutica para la modulacion inmunitaria |
Country Status (35)
Country | Link |
---|---|
US (1) | US7105162B1 (es) |
EP (1) | EP0881906B2 (es) |
JP (1) | JP4184433B2 (es) |
KR (1) | KR100457647B1 (es) |
CN (1) | CN1177610C (es) |
AR (1) | AR005945A1 (es) |
AT (1) | ATE274350T1 (es) |
AU (1) | AU722264B2 (es) |
BG (1) | BG63682B1 (es) |
BR (1) | BR9707694A (es) |
CA (1) | CA2243559C (es) |
CO (1) | CO4600681A1 (es) |
CZ (1) | CZ295396B6 (es) |
DE (1) | DE59711873D1 (es) |
DK (1) | DK0881906T4 (es) |
EE (1) | EE04481B1 (es) |
ES (1) | ES2225951T5 (es) |
HK (1) | HK1017257A1 (es) |
HR (1) | HRP970100B1 (es) |
HU (1) | HU224410B1 (es) |
ID (1) | ID16038A (es) |
IL (1) | IL125361A (es) |
MY (1) | MY119276A (es) |
NO (1) | NO983850L (es) |
NZ (1) | NZ332020A (es) |
PE (1) | PE55398A1 (es) |
PL (1) | PL189413B1 (es) |
PT (1) | PT881906E (es) |
RO (1) | RO119344B1 (es) |
RS (1) | RS50101B (es) |
SI (1) | SI0881906T2 (es) |
SK (1) | SK284582B6 (es) |
TR (1) | TR199801649T2 (es) |
TW (1) | TW585774B (es) |
WO (1) | WO1997030721A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS50101B (sr) | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
ATE247979T1 (de) * | 1998-02-25 | 2003-09-15 | Us Gov Sec Army | Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort |
EP1071411B1 (en) * | 1998-04-20 | 2007-03-14 | Torrey Pines Institute For Molecular Studies | Topical immunostimulation to induce langerhans cell migration |
NZ513935A (en) * | 1999-02-17 | 2004-02-27 | Csl Ltd | Immunogenic complexes and methods relating thereto |
DE19909503A1 (de) * | 1999-03-04 | 2000-09-07 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
US6809179B1 (en) | 1999-08-04 | 2004-10-26 | Boehringer Ingelheim International Gmbh | Tumor-associated antigen (R11) |
AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
AT409085B (de) * | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
AT409762B (de) * | 2000-04-13 | 2002-11-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung von zytokin sekretierenden zellen |
AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
KR20020014459A (ko) * | 2000-08-18 | 2002-02-25 | 서진호 | 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법 |
JP2004519452A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
JP2004519453A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
FR2824326B1 (fr) * | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
WO2003047602A1 (en) * | 2001-12-07 | 2003-06-12 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | C型肝炎ウイルスペプチドの単離方法 |
WO2004035618A2 (en) | 2002-10-15 | 2004-04-29 | Intercell Ag | Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
DE602004022923D1 (de) | 2003-03-04 | 2009-10-15 | Intercell Ag | Streptococcus pyogenes antigene |
ES2562456T3 (es) | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
JP2007523609A (ja) | 2003-03-31 | 2007-08-23 | インターツェル・アクチェンゲゼルシャフト | 表皮ブドウ球菌抗原 |
CA2522238A1 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
JP2007535894A (ja) | 2003-05-07 | 2007-12-13 | インターツェル・アクチェンゲゼルシャフト | ストレプトコッカス・アガラクティエ抗原i+ii |
EP2327720A1 (en) | 2003-05-30 | 2011-06-01 | Intercell AG | Enterococcus antigens |
CN1822856B (zh) | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | Hcv疫苗 |
ES2297688T3 (es) | 2004-03-12 | 2008-05-01 | Intercell Ag | Procedimiento para solubizar mezclas de peptidos. |
DE102004038134B4 (de) | 2004-08-05 | 2013-07-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
ES2344739T3 (es) | 2004-09-24 | 2010-09-06 | Intercell Ag | Proteina capsidial vp1 modificada del parvovirus b19. |
CN101048172A (zh) * | 2004-10-29 | 2007-10-03 | 英特塞尔股份公司 | 用于慢性hcv患者的hcv疫苗 |
US7785612B2 (en) * | 2005-04-20 | 2010-08-31 | Taiho Pharmaceutical Co., Ltd. | Polyamino acid for use as adjuvant |
EP1887084A1 (en) | 2006-08-10 | 2008-02-13 | International Investment and Patents SA | Plasmids with immunological action |
AU2007295927A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
JP2008174490A (ja) * | 2007-01-18 | 2008-07-31 | Nitto Denko Corp | 抗原性ペプチドを主成分とする薬剤 |
US8236326B2 (en) | 2007-05-02 | 2012-08-07 | Intercell Ag | Klebsiella antigens |
KR100748265B1 (ko) * | 2007-06-15 | 2007-08-10 | (주)성문엔지니어링 | 공동주택에 배선된 전선의 합선방지구조 |
EP2167530A2 (en) | 2007-06-18 | 2010-03-31 | Intercell AG | Chlamydia antigens |
BRPI0815008B8 (pt) | 2007-08-02 | 2021-05-25 | Biondvax Pharmaceuticals Ltd | vacinas multiméricas com múltiplos epítopos contra influenza |
WO2009120378A2 (en) * | 2008-03-27 | 2009-10-01 | Nestec S.A. | Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates |
KR20110091560A (ko) | 2008-12-03 | 2011-08-11 | 프로테아 벡신 테크놀로지스 엘티디. | 글루타밀 tRNA 합성효소(GtS) 단편들 |
US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
NZ598459A (en) * | 2009-08-27 | 2014-03-28 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
EP2498764B1 (en) | 2009-11-09 | 2017-09-06 | Spotlight Technology Partners LLC | Fragmented hydrogels |
NZ599524A (en) | 2009-11-09 | 2014-04-30 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
RU2478399C2 (ru) * | 2011-06-16 | 2013-04-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) | Способ получения специфического иммуномодулятора |
US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
MA42420A (fr) | 2015-05-13 | 2018-05-23 | Agenus Inc | Vaccins pour le traitement et la prévention du cancer |
CN109072227A (zh) * | 2016-03-15 | 2018-12-21 | 组库创世纪株式会社 | 用于免疫治疗的监测和诊断及治疗剂的设计 |
MX2018014602A (es) * | 2016-05-27 | 2019-06-10 | Etubics Corp | Composiciones de vacunas neoepitopos y metodos de uso de las mismas. |
US11291718B2 (en) * | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
CN107469067B (zh) * | 2017-09-05 | 2018-06-19 | 浙江大学 | 一种多肽及其改造体在制备免疫调节药物中的应用 |
WO2019210055A2 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CN110870913A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗 |
CN110870912A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1290141A (es) | 1968-05-31 | 1972-09-20 | ||
US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US4728639A (en) * | 1982-07-27 | 1988-03-01 | University Of Tennessee Research Corporation | Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant |
US6022544A (en) * | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US4956273A (en) * | 1985-10-24 | 1990-09-11 | Southwest Foundation For Biomedical Research | Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC |
BE1000587A4 (fr) * | 1986-06-13 | 1989-02-14 | Oncogen | Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. |
DE68925660T2 (de) * | 1988-06-10 | 1996-09-26 | United Biomedical Inc | Peptidfragmente von HIV |
AU4525589A (en) * | 1988-10-27 | 1990-05-14 | Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
CA2072351A1 (en) | 1990-01-05 | 1991-07-06 | Andrew J. Mcmichael | Hiv-1 core protein fragments |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
ATE260679T1 (de) | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
ATE280180T1 (de) | 1992-08-31 | 2004-11-15 | Ludwig Inst Cancer Res | Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5409703A (en) * | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
CZ281462B6 (cs) * | 1993-07-12 | 1996-10-16 | Aliatros Medical, A.S. | Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu |
JP2828391B2 (ja) * | 1993-10-29 | 1998-11-25 | 東燃株式会社 | オリゴ糖を表面に有するリポソーム |
US6660276B1 (en) * | 1994-02-16 | 2003-12-09 | The University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
UY24367A1 (es) | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
RS50101B (sr) | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
-
1997
- 1997-02-20 RS YUP-62/97A patent/RS50101B/sr unknown
- 1997-02-20 CO CO97009092A patent/CO4600681A1/es unknown
- 1997-02-21 CN CNB971925186A patent/CN1177610C/zh not_active Expired - Fee Related
- 1997-02-21 AT AT97905068T patent/ATE274350T1/de active
- 1997-02-21 HU HU9901186A patent/HU224410B1/hu not_active IP Right Cessation
- 1997-02-21 EE EE9800255A patent/EE04481B1/xx unknown
- 1997-02-21 DK DK97905068T patent/DK0881906T4/da active
- 1997-02-21 NZ NZ332020A patent/NZ332020A/en not_active IP Right Cessation
- 1997-02-21 PL PL97328455A patent/PL189413B1/pl unknown
- 1997-02-21 SK SK1145-98A patent/SK284582B6/sk not_active IP Right Cessation
- 1997-02-21 HR HR970100A patent/HRP970100B1/xx not_active IP Right Cessation
- 1997-02-21 BR BR9707694A patent/BR9707694A/pt not_active IP Right Cessation
- 1997-02-21 TR TR1998/01649T patent/TR199801649T2/xx unknown
- 1997-02-21 AU AU18759/97A patent/AU722264B2/en not_active Ceased
- 1997-02-21 MY MYPI97000683A patent/MY119276A/en unknown
- 1997-02-21 SI SI9730672T patent/SI0881906T2/sl unknown
- 1997-02-21 WO PCT/EP1997/000828 patent/WO1997030721A1/de active IP Right Grant
- 1997-02-21 CZ CZ19982689A patent/CZ295396B6/cs not_active IP Right Cessation
- 1997-02-21 CA CA2243559A patent/CA2243559C/en not_active Expired - Fee Related
- 1997-02-21 AR ARP970100701A patent/AR005945A1/es active IP Right Grant
- 1997-02-21 DE DE59711873T patent/DE59711873D1/de not_active Expired - Lifetime
- 1997-02-21 KR KR10-1998-0706339A patent/KR100457647B1/ko not_active IP Right Cessation
- 1997-02-21 ES ES97905068T patent/ES2225951T5/es not_active Expired - Lifetime
- 1997-02-21 RO RO98-01305A patent/RO119344B1/ro unknown
- 1997-02-21 EP EP97905068A patent/EP0881906B2/de not_active Expired - Lifetime
- 1997-02-21 IL IL12536197A patent/IL125361A/en not_active IP Right Cessation
- 1997-02-21 US US09/125,672 patent/US7105162B1/en not_active Expired - Fee Related
- 1997-02-21 JP JP52980697A patent/JP4184433B2/ja not_active Expired - Fee Related
- 1997-02-21 PT PT97905068T patent/PT881906E/pt unknown
- 1997-02-24 ID IDP970541A patent/ID16038A/id unknown
- 1997-02-24 PE PE1997000130A patent/PE55398A1/es not_active IP Right Cessation
- 1997-02-24 TW TW086102221A patent/TW585774B/zh not_active IP Right Cessation
-
1998
- 1998-08-21 NO NO983850A patent/NO983850L/no not_active Application Discontinuation
- 1998-08-21 BG BG102714A patent/BG63682B1/bg active Active
-
1999
- 1999-05-25 HK HK99102360A patent/HK1017257A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR005945A1 (es) | Composicion farmaceutica para la modulacion inmunitaria | |
ES2059565T3 (es) | Virus mva de la vacuna, recombinante. | |
NO20015073D0 (no) | Vaksiner | |
DK1104306T3 (da) | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf | |
AR014181A1 (es) | Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados | |
PE20011217A1 (es) | Composicion farmaceutica para modulacion inmunologica y preparacion de vacunas | |
ATE516299T1 (de) | Chlamydia-antigene | |
CO4700303A1 (es) | Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria | |
ATE397942T1 (de) | Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen | |
NO20020348D0 (no) | Peptid acceptor ligeringsmetoder | |
NO923953L (no) | Peptider | |
AR077759A2 (es) | Anticuerpos bloqueadores de cripto composiciones que los comprenden y usos y metodos que los utilizan | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
ES2196374T3 (es) | Conjugados utiles en el tratamiento del cancer de prostata. | |
ES2123558T3 (es) | Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc. | |
ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
EA199900069A1 (ru) | Вакцинная композиция против малярии | |
AR004341A1 (es) | Vacunas contra tumores y procedimiento para su produccion. | |
ATE424217T1 (de) | Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen | |
SE9903534D0 (sv) | Vaccin | |
ES2127652T3 (es) | Utilizacion del acido silicico coloidal en una composicion de esmalte de uñas. | |
WO2000012122A3 (de) | Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen | |
DE69922212D1 (de) | Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp) | |
ECSP972036A (es) | Composicion farmaceutica para la modulacion inmunitaria | |
CY1107910T1 (el) | Αντιγονα erysipelothrix rhusiopathiae και συνθεσεις εμβολιων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |